Research Evidence
The most significant clinical study on CJC-1295 was published in the Journal of Clinical Endocrinology & Metabolism in 2006. This randomized, placebo-controlled, double-blind trial examined pharmacokinetics, pharmacodynamics, and safety in healthy adults aged 21–61.
Key Findings:
- Single injections produced dose-dependent increases in GH concentrations of 2- to 10-fold lasting 6 or more days
- IGF-1 levels increased 1.5- to 3-fold for 9–11 days after a single dose
- Multiple doses produced cumulative effects, with IGF-1 remaining elevated above baseline for up to 28 days
- No serious adverse reactions were reported
- The peptide was safe and relatively well tolerated, particularly at doses of 30 or 60 μg/kg
Animal Research: A study published in the American Journal of Physiology demonstrated that once-daily administration of CJC-1295 normalized growth in GH-deficient models, supporting its potential therapeutic applications.
Additional Study (2009): Research published in Growth Hormone & IGF Research further confirmed the activation of the GH/IGF-1 axis by CJC-1295, establishing its efficacy as a long-acting GHRH analog.
Important Note: A Phase II clinical trial investigating CJC-1295 for HIV-associated lipodystrophy was halted in 2006 following a patient death, though the relationship to the study drug was not definitively established.